Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris.

J Pharmacol Pharmacother · 2013 · PMC3643340 · PMID 23662022

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

Assessment of antianginal efficacy There was a highly significant difference ( P < 0.01) in the frequency of angina attacks at 2, 4 and 8 weeks of treatment with both IVA and RAN when compared with baseline.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.